Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

KYTX

Kyverna Therapeutics Inc

Feb 18 • 04:00PM ET

7.68

+0.09 1.19 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA AMGN VRTX JNJ REGN GILD BMRN PFE BMY NVAX

| Held by: VTI VXF IBB SURI SCHA IWC AVSC DFAS SCHB DFAC

Index	-	P/E	-	EPS (ttm)	-3.72	Insider Own	38.64%	Shs Outstand	43.79M	Perf Week	-2.17%
Market Cap	438.75M	Forward P/E	-	EPS next Y	-3.47	Insider Trans	1.11%	Shs Float	35.05M	Perf Month	-8.13%
Enterprise Value	272.63M	PEG	-	EPS next Q	-0.85	Inst Own	34.43%	Short Float	10.00%	Perf Quarter	11.63%
Income	-160.99M	P/S	-	EPS this Y	-10.93%	Inst Trans	6.01%	Short Ratio	2.39	Perf Half Y	116.95%
Sales	0.00M	P/B	2.21	EPS next Y	6.11%	ROA	-61.17%	Short Interest	3.51M	Perf YTD	-18.30%
Book/sh	3.47	P/C	2.56	EPS next 5Y	1.16%	ROE	-70.82%	52W High	13.67 -43.82%	Perf Year	158.59%
Cash/sh	3.00	P/FCF	-	EPS past 3/5Y	-75.88% -	ROIC	-105.03%	52W Low	1.78 331.46%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.91% 8.22%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-21.22%	Oper. Margin	-	ATR (14)	0.65	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.16	EPS Q/Q	-6.05%	SMA20	-7.11%	Beta	3.42	Target Price	29.60
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-9.20%	Rel Volume	0.30	Prev Close	7.59
Employees	112	LT Debt/Eq	0.01	Earnings	Nov 12 AMC	SMA200	38.70%	Avg Volume	1.47M	Price	7.68
IPO	Feb 08, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.47% -	Trades		Volume	444,441	Change	1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	William Blair	Outperform
May-27-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Oct-10-24	Initiated	UBS	Buy	$13
Oct-09-24	Initiated	Rodman & Renshaw	Buy	$16
Jul-03-24	Initiated	H.C. Wainwright	Neutral	$8
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-03-26 08:00AM	Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer (GlobeNewswire)
Jan-12-26 08:00AM	Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 08:00AM	Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) -7.30%
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
09:24AM	Loading…
Dec-17-25 09:24AM	Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock (GlobeNewswire) -32.52%
Dec-16-25 10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks) -5.36%
09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
Dec-15-25 04:01PM	Kyverna Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +23.23%
06:30AM	Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome (GlobeNewswire)
03:41AM	Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease (BioPharma Dive)
Dec-14-25 02:30PM	Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome (GlobeNewswire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart) +5.02%
Nov-12-25 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire) -11.60%
Nov-10-25 08:00AM	Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
Nov-03-25 08:00AM	Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance (GlobeNewswire)
Oct-29-25 06:30AM	Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 (GlobeNewswire) -5.78%
Oct-25-25 11:00AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 (GlobeNewswire)
Oct-22-25 08:00AM	Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis (GlobeNewswire) -6.58%
Oct-17-25 09:59AM	Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout (Insider Monkey) -5.42%
Sep-24-25 09:05AM	Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS (GlobeNewswire)
Sep-15-25 01:02PM	Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 (GlobeNewswire)
Aug-28-25 08:00AM	Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event (GlobeNewswire)
Aug-25-25 04:02PM	Kyverna Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire) +14.90%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-29-25 10:23AM	Kyverna Appoints New CFO to Guide Next Growth Phase (Insider Monkey) -11.09%
08:30AM	Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise (PR Newswire)
Jun-30-25 09:00AM	Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM	Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
06:36AM	Loading…
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM	Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM	Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM	Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM	Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM	Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM	Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-17-25 03:01PM	Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-03-25 04:05PM	Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference (PR Newswire) -8.80%
Feb-10-25 12:00PM	What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock (Zacks)
Jan-21-25 04:05PM	Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer (PR Newswire)
Jan-17-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-13-25 07:30AM	Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-08-25 08:00AM	Unnatural Products Appoints Abbas Kazimi and Mert Aktar to Board of Directors (GlobeNewswire)
Jan-07-25 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Jan-06-25 04:05PM	Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference (PR Newswire) -7.07%
Dec-27-24 05:45AM	Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX (PR Newswire)
Dec-19-24 12:16PM	Investors in Kyverna Therapeutics, Inc. Should Contact Levi and Korsinsky Before February 7, 2025 to Discuss Your Rights KYTX (GlobeNewswire)
Dec-13-24 04:05PM	Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth (PR Newswire)
Dec-09-24 06:38PM	Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block and Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire) +6.81% -5.56%
Nov-14-24 10:01AM	Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024 (PR Newswire) -5.14%
Nov-13-24 04:14PM	Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (PR Newswire)
Oct-21-24 08:00AM	Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors (PR Newswire) -7.80%
Oct-19-24 11:13AM	Kyverna Therapeutics (KYTX): Leading Nano Cap with Promising CAR T-Cell Therapy (Insider Monkey)
Oct-10-24 03:05PM	JPMorgan Chase & Co's Strategic Acquisition in Kyverna Therapeutics Inc (GuruFocus.com)
Sep-18-24 08:00AM	Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024 (PR Newswire)
Sep-16-24 08:00AM	Kyverna Therapeutics Announces Leadership Update (PR Newswire)
06:58AM	Kyverna swaps CEOs, leaning on Kite veterans to lead next chapter (BioPharma Dive)
Aug-21-24 04:05PM	Kyverna Therapeutics to Participate in Upcoming September Investor Conferences (PR Newswire) +13.36% -5.36%
Aug-12-24 04:08PM	Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (PR Newswire) +7.20%
04:05PM	Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis (PR Newswire)
Jul-16-24 11:33AM	Kyverna wins RMAT designation for stiff-person syndrome for cell therapy candidate (Pharmaceutical Technology) +11.71%
08:52AM	Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product (Zacks)
Jul-15-24 04:05PM	Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome (PR Newswire)
Jun-20-24 08:55AM	Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial (PR Newswire) +7.93%
Jun-17-24 04:05PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS) (PR Newswire) -17.21% -5.70%
Jun-10-24 04:05PM	Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology (PR Newswire)
Jun-07-24 08:55AM	Kyverna Therapeutics to Present Data on 50 Patient Experience at Symposium at EULAR 2024 (PR Newswire)
May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SEIDENBERG BETH C	Director	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:43 AM
Westlake BioPartners Opportuni	10% Owner	Dec 18 '25	Buy	7.50	133,333	999,998	869,317	Dec 22 11:42 AM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Option Exercise	4.83	23,998	115,910	46,634	Dec 17 08:30 PM
Walker Karen Marie	Chief Technology Officer	Dec 15 '25	Sale	12.20	23,998	292,776	22,636	Dec 17 08:30 PM
KAREN WALKER	Officer	Dec 15 '25	Proposed Sale	8.78	23,998	210,702		Dec 15 04:16 PM

Open in Screener

URGN

UroGen Pharma Ltd

Feb 18 • 04:00PM ET

22.27

+1.67 8.11 %

Healthcare • Biotechnology • USA • NASD

URGN UroGen Pharma Ltd daily Stock Chart

Peers: SRPT BIIB EXEL IONS FOLD ACAD NBIX VKTX PBYI HALO

| Held by: IWM IBB IWO SPDW VTWO FESM IZRL VHT IWC VFMO

Index	RUT	P/E	-	EPS (ttm)	-3.46	Insider Own	17.36%	Shs Outstand	46.78M	Perf Week	2.77%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-1.05	Insider Trans	-0.36%	Shs Float	38.69M	Perf Month	18.46%
Enterprise Value	1.04B	PEG	-	EPS next Q	-0.50	Inst Own	89.40%	Short Float	26.62%	Perf Quarter	-6.27%
Income	-164.64M	P/S	10.80	EPS this Y	-8.01%	Inst Trans	16.19%	Short Ratio	12.99	Perf Half Y	14.79%
Sales	96.52M	P/B	-	EPS next Y	67.19%	ROA	-67.62%	Short Interest	10.30M	Perf YTD	-4.91%
Book/sh	-2.47	P/C	8.12	EPS next 5Y	-	ROE	-	52W High	30.00 -25.77%	Perf Year	110.89%
Cash/sh	2.74	P/FCF	-	EPS past 3/5Y	15.81% 10.39%	ROIC	-1271.96%	52W Low	3.42 551.17%	Perf 3Y	117.91%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	23.46% 449.77%	Gross Margin	87.95%	Volatility	8.39% 6.86%	Perf 5Y	-9.91%
Dividend TTM	-	EV/Sales	10.82	EPS Y/Y TTM	-10.15%	Oper. Margin	-138.22%	ATR (14)	1.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.79	Sales Y/Y TTM	8.00%	Profit Margin	-170.59%	RSI (14)	57.27	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.99	EPS Q/Q	-26.35%	SMA20	7.60%	Beta	1.34	Target Price	35.25
Payout	-	Debt/Eq	-	Sales Q/Q	9.04%	SMA50	3.25%	Rel Volume	1.12	Prev Close	20.60
Employees	235	LT Debt/Eq	-	Earnings	Nov 06 BMO	SMA200	24.74%	Avg Volume	792.87K	Price	22.27
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.33% -15.36%	Trades		Volume	892,954	Change	8.11%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-19-25	Initiated	Piper Sandler	Overweight	$36
Jun-16-25	Upgrade	H.C. Wainwright	Neutral → Buy	$50
May-22-25	Downgrade	H.C. Wainwright	Buy → Neutral
Apr-16-25	Initiated	Scotiabank	Sector Outperform	$23
Feb-19-25	Resumed	Ladenburg Thalmann	Buy	$31
Aug-22-24	Initiated	Guggenheim	Buy	$40
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

Feb-15-26 08:06PM	UroGen Pharma CEO Touts ZUSDURI Launch Momentum, J-Code Boost and Billion-Plus Peak Sales Target (MarketBeat)
Feb-04-26 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-06-26 08:37AM	UroGen Pharma says permanent J Code for ZUSDURI now in effect (TipRanks)
Jan-05-26 08:00AM	Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy (GlobeNewswire)
Dec-05-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.35%
08:00AM	Loading…
Nov-25-25 08:00AM	UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-16-25 10:14PM	UroGen Pharma (URGN) Closes Q3 2025 With $127.4 Million in Cash Amid Rising R&D Costs (Insider Monkey)
Nov-06-25 04:20PM	UroGen Pharma Ltd (URGN) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) +21.91%
09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:00AM	UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI Launch Gains Momentum (GlobeNewswire)
07:58AM	UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial (GlobeNewswire)
Nov-04-25 08:00AM	UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference (GlobeNewswire)
Oct-30-25 10:00AM	Adherex Technologies Inc. (FENC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
08:00AM	UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 (GlobeNewswire)
07:15AM	Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates (Zacks)
10:00AM	Loading…
Oct-29-25 10:00AM	Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 08:00AM	Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 (GlobeNewswire) +9.91%
Oct-22-25 08:18AM	MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? (Zacks)
Oct-02-25 08:00AM	ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Sep-08-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +13.45%
Aug-21-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 03:25AM	UroGen Pharma Ltd (URGN) Q2 2025 Earnings Call Highlights: FDA Approval and Revenue Growth ... (GuruFocus.com)
Aug-07-25 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.10%
08:00AM	UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 08:06AM	UroGens Zusduri benefit maintained in NMIBC Phase III study (Clinical Trials Arena)
Aug-05-25 08:00AM	UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-30-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss (Zacks)
Jul-29-25 08:00AM	UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 (GlobeNewswire)
01:31AM	UroGen Pharma (URGN) Presented Real-World Study of JELMYTO at 2025 American Society of Clinical Oncology (Insider Monkey)
Jul-28-25 08:00AM	UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology (GlobeNewswire)
11:02AM	Loading…
Jul-21-25 11:02AM	3 Bullish Biotech Stocks With Explosive Growth Trends (MarketBeat)
08:00AM	UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-08-25 11:48AM	UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer (Clinical Trials Arena)
Jul-07-25 08:00AM	UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jul-06-25 04:01AM	UroGen Pharma Receives FDA Approval for ZUSDURI for Recurrent Bladder Cancer (Insider Monkey)
Jun-17-25 01:32PM	H.C. Wainwright Sees Billion Dollar Potential in UroGen's New Therapy (Insider Monkey) -7.67%
Jun-13-25 12:40PM	FDA approves UroGens Zusduri for non-muscle invasive bladder cancer (TipRanks) +8.57%
06:00AM	AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans (BioPharma Dive)
05:45AM	UroGen Pharma Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 28, 2025 to Discuss Your Rights - URGN (PR Newswire)
Jun-12-25 01:28PM	U.S. FDA Approves UroGens ZUSDURI (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) +51.78%
Jun-06-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +43.39%
Jun-02-25 11:00AM	UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer (Business Wire) +14.15%
10:00AM	UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
May-29-25 01:45PM	UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman (PR Newswire)
May-27-25 04:00PM	UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Business Wire) -6.21%
May-22-25 06:52AM	FDA advisers pan Pfizers PARP drug; Sarepta to resume Duchenne study (BioPharma Dive)
May-21-25 12:17PM	UroGen Announces Outcome of Oncologic Drugs Advisory Committee for UGN-102 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire) -44.69%
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -5.40%
May-13-25 03:05AM	UroGen Pharma Ltd (URGN) Q1 2025 Earnings Call Highlights: Strong Jelmyto Sales and Promising ... (GuruFocus.com) -8.98%
May-12-25 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.32%
08:00AM	UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-07-25 10:32AM	Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month (Seeking Alpha)
10:22AM	UroGen's bladder cancer treatment to be reviewed by FDA advisory committee (Seeking Alpha)
08:57AM	UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
May-01-25 04:00PM	UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (Business Wire)
Apr-29-25 05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-27-25 04:00PM	OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment (Business Wire)
01:00PM	New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC (Business Wire)
12:30PM	New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC (Business Wire)
Apr-26-25 06:30PM	UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
10:00AM	UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-14-25 08:00AM	UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers (Business Wire)
Apr-12-25 10:02AM	UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy (Seeking Alpha)
Mar-12-25 03:00PM	UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
Mar-10-25 09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102 (Business Wire)
Mar-07-25 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025 (Business Wire)
Feb-25-25 12:30PM	Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now? (Insider Monkey)
Feb-24-25 04:00PM	UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-21-25 10:53AM	UroGen acquires IconOVirs oncolytic virus assets (Pharmaceutical Technology) -5.88%
Feb-20-25 08:00AM	UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations (Business Wire)
Feb-14-25 02:30PM	UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102 (Business Wire)
Feb-12-25 08:00AM	Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology (Business Wire)
Jan-30-25 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Jan-22-25 08:00AM	New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) (Business Wire)
Jan-15-25 08:00AM	ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025 (Business Wire)
Dec-06-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-05-24 03:30PM	Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
03:15PM	UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC (Business Wire)
Dec-02-24 05:44PM	Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade (Zacks)
08:00AM	UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs (Business Wire)
Nov-28-24 11:49AM	UroGen reports long-term data from study of JELMYTO for LG-UTUC treatment (Clinical Trials Arena)
Nov-26-24 08:00AM	New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO (Business Wire)
Nov-07-24 02:16AM	UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Nov-06-24 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 (Business Wire)
Nov-05-24 08:00AM	UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference (Business Wire)
Oct-30-24 08:00AM	UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 (Business Wire) +6.29%
Oct-28-24 08:00AM	ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC (Business Wire)
Oct-16-24 04:47AM	FDA accepts UroGens UGN-102 NDA for bladder cancer treatment (Pharmaceutical Technology)
Oct-15-24 04:30PM	UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 (Business Wire)
Oct-09-24 06:18PM	UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) -9.31%
08:00AM	UroGen Appoints Chris Degnan as Chief Financial Officer (Business Wire)
Oct-03-24 04:12AM	UroGen begins subject dosing in Phase III bladder cancer drug trial (Clinical Trials Arena)
Oct-02-24 08:00AM	First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Sep-23-24 05:50AM	UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now (Insider Monkey)
03:58AM	UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-16-24 08:00AM	UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 (Business Wire)
Sep-05-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Jason Drew	General Counsel	Feb 03 '26	Sale	19.69	7,479	147,262	51,326	Feb 11 02:54 PM
Schoenberg Mark	Chief Medical Officer	Feb 03 '26	Sale	19.69	7,373	145,174	144,985	Feb 04 07:37 PM
Schoenberg Mark	Officer	Feb 02 '26	Proposed Sale	19.61	13,333	261,460		Feb 03 07:53 AM
Schoenberg Mark	Chief Medical Officer	Nov 19 '25	Sale	25.00	10,000	250,000	139,025	Nov 20 01:42 PM
Schoenberg Mark	Officer	Nov 19 '25	Proposed Sale	25.00	10,000	250,005		Nov 19 03:19 PM
Degnan Chris	Chief Financial Officer	Oct 08 '25	Sale	16.85	2,203	37,121	2,280	Oct 09 01:37 PM
Schoenberg Mark	Chief Medical Officer	Sep 08 '25	Sale	19.11	871	16,645	149,025	Sep 09 06:37 PM
Smith Jason Drew	General Counsel	Sep 08 '25	Sale	19.11	1,520	29,047	43,305	Sep 09 06:32 PM
Schoenberg Mark	Officer	Sep 08 '25	Proposed Sale	18.88	871	16,444		Sep 09 09:51 AM
Smith Jason Drew	Officer	Sep 08 '25	Proposed Sale	18.88	1,520	28,698		Sep 09 07:59 AM
Schoenberg Mark	Chief Medical Officer	Aug 11 '25	Sale	17.69	10,000	176,900	148,229	Aug 13 09:58 AM
Smith Jason Drew	General Counsel	Jul 28 '25	Sale	19.14	7,522	143,971	41,492	Jul 30 04:03 PM
Schoenberg Mark	Chief Medical Officer	Jul 28 '25	Sale	19.14	5,149	98,552	158,229	Jul 30 04:02 PM
Schoenberg Mark	Officer	Jul 28 '25	Proposed Sale	18.95	5,149	97,574		Jul 29 07:29 AM
Smith Jason Drew	Officer	Jul 28 '25	Proposed Sale	18.95	7,522	142,542		Jul 29 07:23 AM
Schoenberg Mark	Chief Medical Officer	Jun 09 '25	Sale	7.37	5,162	38,044	153,378	Jun 11 09:14 AM
Schoenberg Mark	Officer	Jun 09 '25	Proposed Sale	7.37	5,162	38,044		Jun 10 09:27 AM

Open in Screener

CDNA

Caredx Inc

Feb 18 • 04:00PM ET

19.93

+0.49 2.52 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: NTRA ILMN FLGT GH EXAS TWST VRTX CRSP TXG QGEN

| Held by: ARKG VTI XBI IWM VXF IWO IBB VTWO SCHA JSMD

Index	RUT	P/E	16.72	EPS (ttm)	1.19	Insider Own	10.88%	Shs Outstand	51.41M	Perf Week	-3.11%
Market Cap	1.03B	Forward P/E	-	EPS next Y	-0.01	Insider Trans	-0.78%	Shs Float	45.84M	Perf Month	-0.40%
Enterprise Value	858.47M	PEG	-	EPS next Q	0.02	Inst Own	99.56%	Short Float	12.55%	Perf Quarter	25.07%
Income	70.45M	P/S	2.86	EPS this Y	-132.11%	Inst Trans	11.83%	Short Ratio	7.81	Perf Half Y	68.19%
Sales	358.00M	P/B	3.29	EPS next Y	96.33%	ROA	15.50%	Short Interest	5.75M	Perf YTD	5.79%
Book/sh	6.05	P/C	5.28	EPS next 5Y	-	ROE	24.11%	52W High	25.55 -22.00%	Perf Year	-18.62%
Cash/sh	3.78	P/FCF	27.64	EPS past 3/5Y	- -	ROIC	21.20%	52W Low	10.96 81.84%	Perf 3Y	27.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	4.04% 21.31%	Gross Margin	66.92%	Volatility	6.15% 5.35%	Perf 5Y	-75.87%
Dividend TTM	-	EV/Sales	2.40	EPS Y/Y TTM	148.22%	Oper. Margin	-7.01%	ATR (14)	1.09	Perf 10Y	283.27%
Dividend Ex-Date	-	Quick Ratio	2.75	Sales Y/Y TTM	14.46%	Profit Margin	19.68%	RSI (14)	51.22	Recom	2.11
Dividend Gr. 3/5Y	- -	Current Ratio	3.03	EPS Q/Q	122.29%	SMA20	-0.81%	Beta	2.51	Target Price	24.00
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	20.72%	SMA50	1.16%	Rel Volume	0.46	Prev Close	19.44
Employees	650	LT Debt/Eq	0.07	Earnings	Feb 24 AMC	SMA200	19.80%	Avg Volume	736.78K	Price	19.93
IPO	Jul 17, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	136.63% 4.91%	Trades		Volume	338,287	Change	2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-06-26	Downgrade	Craig Hallum	Buy → Hold	$26
Aug-26-25	Initiated	William Blair	Mkt Perform
Jan-15-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$28 → $24
Aug-28-24	Initiated	Wells Fargo	Underweight	$28
Aug-19-24	Upgrade	BTIG Research	Neutral → Buy	$40
May-13-24	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-24	Upgrade	Craig Hallum	Hold → Buy	$15
Nov-09-23	Upgrade	Stephens	Equal-Weight → Overweight	$10
Aug-15-23	Upgrade	Raymond James	Mkt Perform → Outperform	$12
May-11-23	Downgrade	BTIG Research	Buy → Neutral
Mar-07-23	Downgrade	Stephens	Overweight → Equal-Weight	$19 → $9
Mar-03-23	Downgrade	Raymond James	Strong Buy → Mkt Perform
Mar-03-23	Downgrade	Craig Hallum	Buy → Hold	$26 → $9
Apr-25-22	Initiated	Stephens	Overweight	$50
Jul-20-21	Resumed	BTIG Research	Buy	$115
Jun-03-21	Initiated	Goldman	Buy	$95
Feb-26-21	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-30-20	Reiterated	H.C. Wainwright	Buy	$47 → $55
Oct-08-20	Reiterated	H.C. Wainwright	Buy	$45 → $47
Oct-02-20	Reiterated	H.C. Wainwright	Buy	$40 → $45

Show Previous Ratings

Feb-18-26 08:00AM	CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference (Business Wire)
Feb-16-26 11:32AM	CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT (Zacks)
Feb-13-26 01:09AM	CareDx Expands Transplant Plus Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data (MarketBeat)
Feb-12-26 07:05AM	CareDx Announces Clinical Validation Results for AlloHeme, the First AI-Powered NGS Surveillance Solution for AML and MDS Post-Cell Therapy (Business Wire)
Feb-10-26 04:01PM	CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (Business Wire)
07:05AM	Loading…
Feb-03-26 07:05AM	CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings (Business Wire)
Jan-27-26 04:05PM	CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:30AM	Implied Volatility Surging for CareDx Stock Options (Zacks)
Jan-12-26 08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks) +20.08%
07:05AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-07-26 07:05AM	CareDx and 10x Genomics to Launch ImmuneScape Program - A Multiomics Research Platform to Decode Transplant Rejection and Drug Response (Business Wire)
Jan-06-26 10:48AM	Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now? (Zacks) -5.05%
Dec-26-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-23-25 09:15AM	Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? (Zacks)
05:00PM	Loading…
Dec-18-25 05:00PM	CareDx Provides Notice of Proposed Derivative Settlement (Business Wire)
Nov-27-25 09:55AM	Wall Street Analysts Believe CareDx (CDNA) Could Rally 28.02%: Here's is How to Trade (Zacks)
Nov-24-25 04:05PM	SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation (Business Wire)
Nov-07-25 04:05PM	CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.91%
Nov-06-25 08:00AM	CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025 (Business Wire) -9.20%
Nov-05-25 12:03AM	CareDx Inc (CDNA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com) +13.84%
Nov-04-25 07:00PM	CareDx (CDNA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:15PM	CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
05:12PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 07:52AM	CareDx Inc (CDNA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 07:05AM	CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer (Business Wire)
Oct-23-25 04:05PM	CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure (Business Wire)
Oct-22-25 04:01PM	CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors (Business Wire)
Oct-21-25 08:00AM	CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
07:05AM	Loading…
Oct-06-25 07:05AM	CareDx Announces New IVD Products and IVDR Certification for AlloSeq Tx and QTYPE at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting (Business Wire)
Sep-02-25 04:01PM	CareDx Issues Comment Letter on Draft LCD Policy (Business Wire) -8.09%
Aug-26-25 01:08PM	CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential (Benzinga)
Aug-22-25 08:30AM	Do Options Traders Know Something About CareDx Stock We Don't? (Zacks)
Aug-21-25 04:01PM	CareDx to Participate in Wells Fargo Healthcare Conference (Business Wire)
Aug-12-25 08:00AM	Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors (Business Wire) +5.86%
Aug-06-25 06:30PM	Here's What Key Metrics Tell Us About CareDx (CDNA) Q2 Earnings (Zacks) -7.86%
05:45PM	CareDx (CDNA) Lags Q2 Earnings and Revenue Estimates (Zacks)
04:57PM	CareDx Announces Appointment of Nathan Smith as Chief Financial Officer (Business Wire)
04:43PM	CareDx: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	CareDx Announces Second Quarter 2025 Financial Results (Business Wire)
12:56PM	CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation (Business Wire)
Aug-05-25 10:07AM	What To Expect From CareDx Inc (CDNA) Q2 2025 Earnings (GuruFocus.com)
Jul-31-25 04:01PM	CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress (Business Wire)
Jul-23-25 07:05AM	CareDx to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-22-25 07:06AM	CareDx (CDNA) Surges 7.0%: Is This an Indication of Further Gains? (Zacks)
Jul-18-25 08:00AM	CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection (Business Wire)
Jun-03-25 04:30PM	CareDx Announces Repurchase of 5% of Outstanding Shares (Business Wire) +10.67%
May-13-25 04:01PM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-01-25 03:17AM	CareDx Inc (CDNA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Strategic Investments (GuruFocus.com) -10.72%
Apr-30-25 08:39PM	CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript (Seeking Alpha) -6.89%
05:50PM	CareDx (CDNA) Tops Q1 Earnings Estimates (Zacks)
04:50PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2025 Results (Business Wire)
Apr-29-25 07:05AM	CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-24-25 07:05AM	CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting (Business Wire)
Apr-21-25 04:01PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-08-25 07:05AM	CareDx to Report First Quarter 2025 Financial Results (Business Wire)
Apr-04-25 12:40PM	Elevance Health (ELV) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-11-25 07:05AM	CareDx Launches Two Expanded Indications for AlloSure Testing Services (Business Wire)
Feb-27-25 02:20AM	CareDx Inc (CDNA) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-25 07:00PM	CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:56PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-25-25 10:39AM	CareDx Inc (CDNA) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
07:05AM	CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict (Business Wire)
Feb-20-25 07:05AM	CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients (Business Wire) -5.34%
Feb-13-25 07:05AM	CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies (Business Wire)
Feb-11-25 07:05AM	CareDx to Report Fourth Quarter and Full Year 2024 Financial Results (Business Wire) -8.43%
03:22AM	CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock? (Zacks)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV) +11.16%
02:51PM	Final Trades: NRG Energy, MP Materials, CareDx and Applovin (CNBC TV)
Feb-05-25 09:55AM	Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect? (Zacks)
Jan-29-25 09:40AM	Is CareDx (CDNA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-28-25 08:19AM	CareDx (CDNA) Traded Down Due to Disappointing Quarterly Results (Insider Monkey)
Jan-24-25 08:35AM	Heres Why CareDx (CDNA) Traded Lower in Q4 (Insider Monkey)
Jan-15-25 03:50PM	Wells Fargo upgrades CareDx after a 30% pullback in stock (Investing.com)
Jan-14-25 03:43AM	Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength? (Zacks) -12.05%
Jan-13-25 07:00AM	CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results (Business Wire) +6.09%
Jan-06-25 09:35AM	Implied Volatility Surging for CareDx (CDNA) Stock Options (Zacks)
Dec-18-24 07:05AM	CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) -7.86%
Dec-11-24 07:00AM	TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (PR Newswire)
07:00AM	CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy (Business Wire)
Dec-03-24 09:40AM	Has CareDx (CDNA) Outpaced Other Medical Stocks This Year? (Zacks)
Nov-29-24 10:46AM	Higher-Than-Anticipated Reimbursement Rates Lifted CareDx (CDNA) (Insider Monkey)
Nov-25-24 09:55AM	Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know (Zacks)
Nov-15-24 09:35AM	After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA) (Zacks)
Nov-14-24 09:40AM	Are Medical Stocks Lagging CareDx (CDNA) This Year? (Zacks) -5.40%
Nov-12-24 07:05AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
Nov-07-24 09:04AM	Accelerated Testing Volume Lifted CareDx (CDNA) in Q3 (Insider Monkey)
Nov-05-24 01:03PM	Q3 2024 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
02:06AM	CareDx Inc (CDNA) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-04-24 05:03PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Third Quarter 2024 Results and Raises Revenue Guidance (Business Wire)
Oct-23-24 07:00AM	CareDx and Dovetail Genomics Announce Strategic Partnership to Drive Next Wave of Innovation in Transplant Matching with Cutting-Edge Hi-C Technology (Business Wire)
Oct-21-24 07:00AM	CareDx Showcases Latest Advancements Across its HLA Typing Solutions at Annual American Society for Histocompatibility and Immunogenetics Meeting (Business Wire)
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in CareDx Inc Holdings (GuruFocus.com) -6.49%
Oct-16-24 08:17AM	CareDx Reports Strong Q3 2024 Revenue Growth (TipRanks)
Oct-15-24 06:00AM	CareDx Reports Preliminary Financial Results for Third Quarter 2024 (Business Wire) -15.84%
Oct-11-24 04:30PM	CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Novack Jeffrey Adam	Secretary and General Counsel	Feb 03 '26	Sale	20.56	4,441	91,286	125,364	Feb 04 04:22 PM
JEFFREY NOVACK	Officer	Feb 03 '26	Proposed Sale	20.42	4,441	90,685		Feb 03 04:33 PM
Hanna John Walter JR	President and CEO	Jan 22 '26	Sale	21.16	19,280	408,023	597,405	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 21 '26	Sale	21.00	200	4,200	616,685	Jan 23 05:58 PM
Hanna John Walter JR	President and CEO	Jan 15 '26	Sale	21.05	10,156	213,804	616,885	Jan 20 05:30 PM
JOHN HANNA	Director	Jan 15 '26	Proposed Sale	20.32	29,636	602,204		Jan 15 04:40 PM
Novack Jeffrey Adam	Secretary and General Counsel	Dec 04 '25	Sale	19.17	7,293	139,804	97,925	Dec 05 04:07 PM
JEFFREY NOVACK	Officer	Dec 04 '25	Proposed Sale	18.85	7,293	137,473		Dec 04 04:39 PM
Novack Jeffrey Adam	Secretary and General Counsel	Nov 07 '25	Sale	15.52	2,688	41,723	105,218	Nov 10 04:14 PM
Jeffrey Adam Novack	Officer	Nov 07 '25	Proposed Sale	15.01	2,688	40,347		Nov 07 04:37 PM
ABHISHEK JAIN	Officer	Nov 05 '25	Proposed Sale	15.77	53,388	842,050		Nov 05 04:21 PM
ABHISHEK JAIN	Officer	Oct 31 '25	Proposed Sale	14.90	9,964	148,464		Oct 31 04:48 PM
Bickerstaff George	Director	Sep 11 '25	Option Exercise	7.96	29,136	231,923	144,266	Sep 12 05:09 PM
Novack Jeffrey Adam	Secretary and General Counsel	Aug 05 '25	Sale	12.79	2,688	34,381	112,930	Aug 07 04:00 PM
Jeffrey Adam Novack	Officer	Aug 05 '25	Proposed Sale	12.60	2,688	33,869		Aug 05 04:27 PM
Maag Peter	Director	Jul 07 '25	Sale	18.58	10,000	185,831	308,846	Jul 10 04:04 PM
Valantine Hannah	Director	Jun 18 '25	Sale	19.16	10,570	202,566	38,994	Jun 23 04:30 PM
Maag Peter	Director	Jun 17 '25	Sale	19.24	10,000	192,420	318,846	Jun 20 04:30 PM
HANNAH VALANTINE	Director	Jun 18 '25	Proposed Sale	19.52	10,570	206,326		Jun 18 04:26 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Option Exercise	13.20	19,391	256,052	73,370	Jun 13 05:06 PM
HAGSTROM WILLIAM A	Director	Jun 11 '25	Sale	19.90	19,391	385,918	53,979	Jun 13 05:06 PM
WILLIAM HAGSTROM	Director	Jun 11 '25	Proposed Sale	19.90	19,391	385,918		Jun 11 04:20 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Option Exercise	7.45	30,000	223,441	83,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Sale	17.45	30,000	523,413	53,979	May 30 05:57 PM
HAGSTROM WILLIAM A	Director	May 28 '25	Proposed Sale	17.63	30,000	528,900		May 28 05:01 PM
COURNOYER CHRISTINE	Director	May 12 '25	Option Exercise	7.96	29,136	231,923	66,181	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Sale	15.96	29,136	465,022	37,045	May 14 05:18 PM
COURNOYER CHRISTINE	Director	May 12 '25	Proposed Sale	15.96	29,136	465,021		May 12 05:15 PM
Christine M. Cournoyer	Director	May 12 '25	Proposed Sale	15.36	12,000	184,320		May 12 05:10 PM
COURNOYER CHRISTINE	Director	May 06 '25	Sale	14.13	16,700	235,929	37,045	May 08 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	May 05 '25	Sale	14.70	2,688	39,514	121,350	May 07 04:38 PM
Christine M. Cournoyer	Director	May 06 '25	Proposed Sale	15.17	16,700	253,339		May 06 05:00 PM
Jeffrey Adam Novack	Officer	May 05 '25	Proposed Sale	15.00	2,688	40,320		May 05 04:39 PM
Maag Peter	Director	Apr 30 '25	Sale	17.23	13,281	228,796	316,743	May 02 04:49 PM
PETER MAAG	Director	Apr 30 '25	Proposed Sale	18.13	33,281	603,385		Apr 30 04:18 PM
Jain Abhishek	Chief Financial Officer	Apr 07 '25	Sale	17.72	265	4,696	337,418	Apr 09 04:31 PM
Novack Jeffrey Adam	Secretary and General Counsel	Apr 07 '25	Sale	17.72	924	16,373	126,911	Apr 09 04:30 PM
Bickerstaff George	Director	Mar 10 '25	Sale	18.36	20,000	367,102	103,027	Mar 12 04:30 PM
GEORGE W BICKERSTAFF	Director	Mar 10 '25	Proposed Sale	18.36	20,000	367,102		Mar 10 05:03 PM

Open in Screener

NTLA

Intellia Therapeutics Inc

Feb 18 • 04:00PM ET

12.48

+0.26 2.13 %

Healthcare • Biotechnology • USA • NASD

NTLA Intellia Therapeutics Inc daily Stock Chart

Peers: CRSP BEAM EDIT BNTX SGMO REPL CLLS FDMT PSTX ADPT

| Held by: ARKK VTI XBI ARKG VB IWM VBK VXF IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-4.27	Insider Own	5.12%	Shs Outstand	115.79M	Perf Week	4.79%
Market Cap	1.45B	Forward P/E	-	EPS next Y	-3.63	Insider Trans	1.30%	Shs Float	109.90M	Perf Month	-0.16%
Enterprise Value	1.03B	PEG	-	EPS next Q	-0.93	Inst Own	86.70%	Short Float	41.24%	Perf Quarter	43.45%
Income	-445.81M	P/S	25.13	EPS this Y	24.14%	Inst Trans	1.49%	Short Ratio	9.54	Perf Half Y	16.31%
Sales	57.53M	P/B	1.93	EPS next Y	8.84%	ROA	-42.49%	Short Interest	45.32M	Perf YTD	38.82%
Book/sh	6.46	P/C	2.83	EPS next 5Y	66.06%	ROE	-52.11%	52W High	28.25 -55.82%	Perf Year	8.24%
Cash/sh	4.41	P/FCF	-	EPS past 3/5Y	-11.59% -20.04%	ROIC	-54.43%	52W Low	5.90 111.53%	Perf 3Y	-69.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	20.53% 6.07%	Gross Margin	78.27%	Volatility	6.41% 9.04%	Perf 5Y	-81.26%
Dividend TTM	-	EV/Sales	17.95	EPS Y/Y TTM	21.66%	Oper. Margin	-820.86%	ATR (14)	0.98	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.21	Sales Y/Y TTM	33.52%	Profit Margin	-774.94%	RSI (14)	52.27	Recom	2.12
Dividend Gr. 3/5Y	- -	Current Ratio	6.21	EPS Q/Q	31.56%	SMA20	-4.24%	Beta	2.12	Target Price	26.82
Payout	-	Debt/Eq	0.13	Sales Q/Q	51.27%	SMA50	11.60%	Rel Volume	0.52	Prev Close	12.22
Employees	403	LT Debt/Eq	0.09	Earnings	Nov 06 AMC	SMA200	3.77%	Avg Volume	4.75M	Price	12.48
IPO	May 06, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.48% -0.94%	Trades		Volume	2,517,846	Change	2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight	$5
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$14
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$33
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$21
Mar-05-25	Initiated	H.C. Wainwright	Buy	$30
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral	$45 → $13
Feb-28-25	Downgrade	Goldman	Neutral → Sell	$9
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$56 → $11
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39

Show Previous Ratings

Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
Feb-15-26 08:41AM	H.C. Wainwright Boosts Intellia (NTLA) Price Target After MAGNITUDE-2 Hold Lifted (Insider Monkey)
Feb-09-26 08:02AM	Take the Zacks Approach to Beat the Markets: Hershey's, Fastenal, Kennametal in Focus (Zacks)
Feb-06-26 07:30AM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.73%
Feb-04-26 07:27PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -5.29% -10.28%
09:37AM	Loading…
Feb-02-26 09:37AM	Baird Updates Intellia Therapeutics, Inc. (NTLA)'s Financial Model Following Nex-Z Clinical Hold Removal (Insider Monkey)
08:25AM	Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks) -6.81%
07:35AM	Intellia Therapeutics (NTLA) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
06:33AM	Intellia Therapeutics to resume dosing of gene therapy in Phase III trial (Clinical Trials Arena)
Jan-27-26 04:04PM	The Gene-Editing News That Sent Beleaguered Intellia Therapeutics Stock Up (Investor's Business Daily) +6.31%
01:03PM	Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder (Benzinga)
08:31AM	Intellia gets FDA nod to resume gene therapy trial after safety pause (Reuters)
08:00AM	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN (GlobeNewswire)
06:59AM	FDA lifts hold on an Intellia CRISPR drug trial (BioPharma Dive)
08:47PM	Loading…
Jan-22-26 08:47PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) +13.33% -7.99%
Jan-19-26 01:27PM	Cathie Wood Buys AI Chips, Sells Tesla (GuruFocus.com)
Jan-15-26 10:56AM	JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death (Clinical Trials Arena)
Jan-14-26 09:30AM	Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average (Zacks)
Jan-07-26 07:30AM	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-05-26 12:23PM	ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure (GuruFocus.com)
10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
Jan-02-26 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-31-25 01:33PM	Cathie Wood shells out $1.3 million on biotech stock (TheStreet)
09:32AM	Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry? (Zacks)
06:26AM	Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab (GuruFocus.com)
Dec-30-25 07:35AM	What Makes Intellia Therapeutics (NTLA) an Interesting Investment? (Insider Monkey)
Dec-29-25 09:50AM	2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street (Motley Fool)
Dec-05-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-25 01:41PM	Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory (Insider Monkey) +7.51%
08:00AM	Loading…
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-28-25 09:59AM	Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry? (Zacks) +5.52%
Nov-27-25 08:15AM	BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential? (Zacks)
Nov-25-25 08:39AM	Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress (Insider Monkey)
Nov-21-25 10:19AM	NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-18-25 08:48AM	Top 3 Genomics Stocks to Consider for Your Portfolio (Zacks)
04:45AM	Evercore Downgrades Intellia (NTLA) Despite Strong ATTR Trial Data (Insider Monkey)
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 08:58AM	Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks? (Zacks)
Nov-13-25 09:00AM	Should You Buy the Dip in Intellia Therapeutics Stock? (Barchart) -8.64%
Nov-12-25 09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly) -6.78%
Nov-11-25 07:30AM	Is This Beaten-Down Cathie Wood Stock Still a Buy? (Barchart)
Nov-10-25 03:17PM	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
01:19PM	Why Gene-Editing Giants Crispr Therapeutics And Intellia Therapeutics Diverged (Investor's Business Daily)
Nov-08-25 05:28PM	More Drugs to Fight High Cholesterol Are Emerging (The Wall Street Journal)
05:13PM	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (GlobeNewswire)
Nov-07-25 05:09PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -22.73%
04:14PM	Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies (Investor's Business Daily)
10:55AM	Intellia Therapeutics Says a Patient Died in Gene Editing Trial (Barrons.com)
09:56AM	Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble (Zacks)
08:45AM	2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street (Motley Fool)
Nov-06-25 05:20PM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -9.21%
04:00PM	Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
Nov-05-25 11:35AM	VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve? (Zacks) +11.23%
11:27AM	MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened (Zacks)
Nov-04-25 10:41AM	Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint (Zacks) -6.66%
10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
10:26AM	TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised (Zacks)
Nov-03-25 10:11AM	Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? (Zacks)
Nov-02-25 09:25AM	Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130% (Motley Fool)
Oct-31-25 01:44PM	AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues (Zacks)
10:00AM	ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-30-25 07:14PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research) -6.52%
06:54AM	FDA places formal hold on two Intellia CRISPR trials (BioPharma Dive)
Oct-29-25 06:05PM	Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates (Zacks) -6.02%
Oct-28-25 12:43PM	CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause (GuruFocus.com) -5.61%
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
Oct-27-25 12:03PM	Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial (Barrons.com) -42.23%
08:25AM	Intellia stock tumbles after pausing gene therapy trials on safety concerns (Investing.com)
08:00AM	Intellia pauses two CRISPR drug studies after safety scare (BioPharma Dive)
07:30AM	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) (GlobeNewswire)
Oct-21-25 12:56PM	Intellia (NTLA) Soars 13% to Fresh High (Insider Monkey)
Oct-20-25 09:25AM	Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition? (Zacks) +13.05%
09:16AM	Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus (Zacks)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 09:23AM	Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? (Zacks)
04:59AM	Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger 'Buy' (Insider Monkey)
Oct-08-25 12:00PM	Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know (Zacks) +19.72%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
09:55AM	Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know (Zacks)
09:40AM	Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:45AM	1 Stock Up by 63% This Year That Could Double, According to Wall Street (Motley Fool)
Oct-06-25 08:07AM	Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus (Zacks)
Oct-03-25 04:01PM	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 10:47AM	Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought (Motley Fool) +8.63%
Sep-25-25 01:57PM	Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug (Benzinga) -6.48%
09:52AM	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-22-25 09:09AM	Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus (Zacks) +10.71%
07:30AM	Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy (GlobeNewswire)
Sep-19-25 12:24PM	NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up (Zacks)
09:20AM	Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength? (Zacks)
Sep-18-25 07:30AM	Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema (GlobeNewswire) +29.81%
Sep-11-25 03:45AM	Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190% (Motley Fool)
Sep-10-25 11:30AM	Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report? (Zacks)
Sep-02-25 03:46PM	Cathie Wood Pours $4 Million Into This High-Growth Biotech Stock (GuruFocus.com)
09:03AM	Beat the Market the Zacks Way: Oracle, Intellia, Pharming Group in Focus (Zacks)
Aug-29-25 10:22AM	Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy? (Zacks)
Aug-21-25 11:15AM	CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock (Zacks)
10:59AM	Cathie Wood Is Betting Big on Intellia Therapeutics. Should You Buy NTLA Stock Here? (Barchart)
Aug-12-25 11:40AM	Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? (Zacks)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEONARD JOHN M	President and CEO	Jan 05 '26	Sale	9.21	34,146	314,485	1,013,339	Jan 07 04:05 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Jan 05 '26	Sale	9.21	8,508	78,359	98,533	Jan 07 04:05 PM
BASTA JAMES	EVP, General Counsel	Jan 05 '26	Sale	9.21	10,397	95,756	101,528	Jan 07 04:05 PM
Cohen Fred E	Director	Jan 05 '26	Buy	9.35	150,000	1,402,500	207,453	Jan 07 04:05 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 05 '26	Sale	9.21	11,903	109,627	121,249	Jan 07 04:04 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 05 '26	Sale	9.21	9,515	87,633	87,118	Jan 07 04:03 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jan 05 '26	Sale	9.21	6,379	58,751	99,683	Jan 07 04:02 PM
Dube Michael P	VP, Chief Accounting Officer	Jan 05 '26	Sale	9.21	2,989	27,529	52,277	Jan 07 04:01 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Option Exercise	6.83	49,959	341,220	1,127,074	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 12 '25	Option Exercise	6.83	8,557	58,444	1,047,485	Dec 12 04:09 PM
LEONARD JOHN M	President and CEO	Dec 11 '25	Sale	9.49	88,146	836,384	1,038,928	Dec 12 04:09 PM
LEONARD JOHN M	Officer	Dec 11 '25	Proposed Sale	9.33	88,146	822,402		Dec 11 04:11 PM
Schultes Birgit C	EVP, Chief Scientific Officer	Oct 01 '25	Sale	17.38	31	539	105,184	Oct 03 05:13 PM
Dube Michael P	VP, Chief Accounting Officer	Oct 01 '25	Sale	17.38	1,871	32,518	55,266	Oct 03 05:13 PM
CHASE WILLIAM J	Director	Aug 20 '25	Buy	10.03	100,000	1,003,000	134,693	Aug 22 04:30 PM
Dulac Edward J III	EVP, Chief Financial Officer	Jul 23 '25	Sale	14.02	7,462	104,617	106,062	Jul 25 04:05 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 01 '25	Sale	9.82	1,022	10,036	95,369	Jul 03 04:11 PM
Dube Michael P	VP, Chief Accounting Officer	Jul 02 '25	Sale	9.95	2,503	24,905	57,137	Jul 03 04:07 PM
GOODMAN JESSE	Director	Jun 30 '25	Sale	9.56	1,547	14,789	25,906	Jul 02 05:50 PM
GOODMAN JESSE	Director	Jul 01 '25	Sale	9.23	1,547	14,279	24,359	Jul 02 05:50 PM
Bhanji Muna	Director	Apr 29 '25	Sale	8.50	265	2,252	19,203	May 01 04:24 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '25	Sale	8.99	679	6,104	95,369	Mar 04 04:43 PM
BASTA JAMES	EVP, General Counsel	Mar 04 '25	Sale	8.99	2,572	23,122	111,925	Mar 04 04:21 PM

Open in Screener

PGNY

Progyny Inc

Feb 18 • 04:00PM ET

20.36

+0.01 0.05 %

Healthcare • Healthcare Plans • USA • NASD

Peers: OSCR CNC MOH HUM UNH CVS CI CLOV GDRX AMWL

| Held by: IJR VTI VB IWM VBK VXF SPSM IJT IWO VTWO

Index	RUT	P/E	32.24	EPS (ttm)	0.63	Insider Own	16.13%	Shs Outstand	86.15M	Perf Week	-5.39%
Market Cap	1.76B	Forward P/E	21.71	EPS next Y	0.94	Insider Trans	0.37%	Shs Float	72.31M	Perf Month	-16.97%
Enterprise Value	1.44B	PEG	0.84	EPS next Q	0.15	Inst Own	93.09%	Short Float	3.94%	Perf Quarter	-17.07%
Income	56.57M	P/S	1.38	EPS this Y	15.61%	Inst Trans	3.56%	Short Ratio	2.01	Perf Half Y	-14.38%
Sales	1.27B	P/B	3.13	EPS next Y	42.34%	ROA	7.77%	Short Interest	2.85M	Perf YTD	-20.72%
Book/sh	6.50	P/C	5.08	EPS next 5Y	25.91%	ROE	11.37%	52W High	28.75 -29.18%	Perf Year	-10.66%
Cash/sh	4.00	P/FCF	9.07	EPS past 3/5Y	-4.58% -	ROIC	9.67%	52W Low	17.98 13.26%	Perf 3Y	-39.42%
Dividend Est.	-	EV/EBITDA	15.93	Sales past 3/5Y	32.60% 38.42%	Gross Margin	22.94%	Volatility	3.98% 3.78%	Perf 5Y	-58.47%
Dividend TTM	-	EV/Sales	1.13	EPS Y/Y TTM	8.70%	Oper. Margin	6.77%	ATR (14)	0.93	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.96	Sales Y/Y TTM	11.41%	Profit Margin	4.46%	RSI (14)	25.57	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	2.96	EPS Q/Q	38.34%	SMA20	-11.18%	Beta	1.00	Target Price	30.91
Payout	0.00%	Debt/Eq	0.05	Sales Q/Q	9.32%	SMA50	-17.65%	Rel Volume	0.82	Prev Close	20.35
Employees	680	LT Debt/Eq	0.04	Earnings	Feb 26 AMC	SMA200	-10.86%	Avg Volume	1.42M	Price	20.36
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.92% 4.71%	Trades		Volume	1,179,298	Change	0.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-20-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$30
Jan-08-26	Upgrade	Truist	Hold → Buy	$34
Dec-09-25	Initiated	Barclays	Overweight	$29
Nov-12-25	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$30
Jul-08-25	Upgrade	Leerink Partners	Market Perform → Outperform	$28
Dec-02-24	Downgrade	JP Morgan	Overweight → Neutral	$17
Nov-13-24	Downgrade	Truist	Buy → Hold	$26 → $19
Sep-19-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-07-24	Downgrade	Leerink Partners	Outperform → Market Perform	$31 → $25
Aug-07-24	Downgrade	Canaccord Genuity	Buy → Hold	$37 → $24
Aug-07-24	Downgrade	BTIG Research	Buy → Neutral
Jul-16-24	Initiated	JMP Securities	Mkt Outperform	$36
May-10-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Feb-26-24	Initiated	Leerink Partners	Outperform	$49
Jan-03-24	Initiated	Barclays	Overweight	$48
Sep-27-23	Initiated	Canaccord Genuity	Buy	$46
May-22-23	Initiated	BTIG Research	Buy	$50
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight	$44
Jan-05-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$34
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$55

Show Previous Ratings

Feb-12-26 02:46PM	Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2025 Results Report (GlobeNewswire)
Jan-22-26 07:20AM	Progyny price target raised to $35 from $30 at BTIG (TipRanks)
03:23AM	Progyny, Inc. (PGNY) Supported by Analysts as Earnings Visibility Improves (Insider Monkey)
Jan-20-26 03:10PM	Progyny (PGNY) Stock Is Up, What You Need To Know (StockStory)
Jan-14-26 11:35PM	3 Hyped Up Stocks That Concern Us (StockStory) -6.93%
10:07AM	Loading…
Jan-12-26 10:07AM	Zacks Industry Outlook Highlights Medpace, Enhabit and Progyny (Zacks) +5.30%
08:00AM	Progyny to Discuss Updated Financial Expectations at Upcoming JP Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 09:15AM	Progyny, Inc. (PGNY) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:04AM	3 Medical Service Industry Stocks Set to Tackle Workforce Challenges (Zacks)
Jan-08-26 11:36AM	Progyny (PGNY) Stock Is Up, What You Need To Know (StockStory)
Dec-31-25 11:04PM	2 Reasons PGNY is Risky and 1 Stock to Buy Instead (StockStory)
Dec-23-25 09:15AM	Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.16%
Dec-22-25 09:15AM	BrightSpring Health Services, Inc. (BTSG) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-16-25 11:32PM	3 Healthcare Stocks We're Skeptical Of (StockStory)
Dec-15-25 12:00PM	Progyny (PGNY) Upgraded to Buy: Here's What You Should Know (Zacks)
11:31PM	Loading…
Dec-08-25 11:31PM	1 Russell 2000 Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Dec-07-25 11:39PM	2 Stocks Under $50 on Our Watchlist and 1 We Find Risky (StockStory)
Nov-25-25 09:15AM	Pediatrix Medical Group, Inc. (MD) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-24-25 12:45PM	Is Progyny (PGNY) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Nov-20-25 09:23AM	New Men's Health Research from Progyny Challenges Conventional Beliefs about Fertility Knowledge and Action (GlobeNewswire)
Nov-18-25 09:15AM	Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-17-25 10:37PM	A Look Back at Health Insurance Providers Stocks' Q3 Earnings: Progyny (NASDAQ:PGNY) Vs The Rest Of The Pack (StockStory) +9.25%
Nov-14-25 11:40AM	PGNY vs. HQY: Which Stock Is the Better Value Option? (Zacks)
Nov-13-25 12:33PM	Progyny, Inc. to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
12:37AM	5 Must-Read Analyst Questions From Progyny's Q3 Earnings Call (StockStory)
Nov-12-25 11:35PM	3 Inflated Stocks with Warning Signs (StockStory)
09:45AM	Carvana initiated, AT upgraded: Wall Street's top analyst calls (The Fly)
Nov-07-25 01:02PM	Why Progyny Stock Is Soaring Today (Motley Fool) +24.21%
09:21AM	PGNY Q3 Deep Dive: Product Expansion and Client Diversification Drive Momentum (StockStory)
12:08AM	Progyny Inc (PGNY) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions (GuruFocus.com)
05:20PM	Loading…
Nov-06-25 05:20PM	Progyny (PGNY) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:13PM	Progyny: Q3 Earnings Snapshot (Associated Press Finance)
04:08PM	Progyny (NASDAQ:PGNY) Reports Upbeat Q3, Stock Soars (StockStory)
04:01PM	Progyny, Inc. Announces Third Quarter 2025 Results (GlobeNewswire)
Nov-05-25 07:36AM	Earnings To Watch: Progyny Inc (PGNY) Reports Q3 2025 Result (GuruFocus.com)
Nov-04-25 10:09PM	Progyny (PGNY) Q3 Earnings: What To Expect (StockStory)
Oct-27-25 03:13AM	3 Small-Cap Stocks with Warning Signs (StockStory)
Oct-23-25 01:08PM	Progyny, Inc. Announces Details for Its Third Quarter 2025 Results Report (GlobeNewswire)
09:40AM	Are Investors Undervaluing Progyny (PGNY) Right Now? (Zacks)
Oct-22-25 04:55PM	Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks (Motley Fool)
09:28AM	Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause (GlobeNewswire)
Oct-07-25 09:40AM	Is Progyny (PGNY) Stock Undervalued Right Now? (Zacks)
09:30AM	Progyny CEO Named World Economic Forum Champion for Women's Health (GlobeNewswire)
Oct-02-25 12:04AM	3 Reasons to Avoid PGNY and 1 Stock to Buy Instead (StockStory)
Sep-26-25 08:05AM	A Healthcare Debate: Progyny vs. Hims & Hers (Motley Fool)
Sep-15-25 11:32PM	Health Insurance Providers Stocks Q2 Results: Benchmarking Progyny (NASDAQ:PGNY) (StockStory)
Sep-05-25 02:36PM	Why Progyny (PGNY) Stock Is Trading Lower Today (StockStory)
Sep-01-25 12:20PM	Surging Earnings Estimates Signal Upside for Progyny (PGNY) Stock (Zacks)
09:15AM	CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-27-25 12:32PM	Progyny (PGNY) Stock Trades Up, Here Is Why (StockStory)
Aug-21-25 12:33AM	1 Russell 2000 Stock with Impressive Fundamentals and 2 We Ignore (StockStory)
Aug-18-25 02:40PM	Progyny (PGNY) Stock Is Up, What You Need To Know (StockStory)
Aug-14-25 01:35AM	5 Must-Read Analyst Questions From Progyny's Q2 Earnings Call (StockStory)
Aug-12-25 09:00AM	URA Advances Womens Health with First-of-its-Kind Support for Pregnancy and Menopause, Bridging Gaps in Care with Personalized Biometrics and Clinical Integrations (Business Wire)
03:07AM	PGNY Q2 Deep Dive: Product Expansion and Client Diversification Drive Upbeat Guidance (StockStory)
Aug-08-25 03:38AM	Progyny Inc (PGNY) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Partnerships ... (GuruFocus.com)
Aug-07-25 06:20PM	Progyny (PGNY) Tops Q2 Earnings and Revenue Estimates (Zacks)
05:30PM	Progyny: Q2 Earnings Snapshot (Associated Press Finance)
04:48PM	Progyny (NASDAQ:PGNY) Beats Expectations in Strong Q2, Full-Year Sales Guidance is Optimistic (StockStory)
04:02PM	Progyny, Inc. Announces Second Quarter 2025 Results (GlobeNewswire)
Aug-05-25 11:16PM	Progyny Earnings: What To Look For From PGNY (StockStory)
Aug-04-25 06:15PM	Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-01-25 07:15AM	BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-31-25 10:00AM	Progyny (PGNY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-30-25 09:19AM	New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage (GlobeNewswire)
Jul-24-25 12:10PM	Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jul-21-25 01:15PM	Why Progyny (PGNY) Stock Is Up Today (StockStory)
Jul-18-25 12:25PM	Why Progyny (PGNY) Stock Is Falling Today (StockStory)
Jul-10-25 09:06AM	Progyny Partners with URA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause (GlobeNewswire)
09:06AM	Progyny Partners with OURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause (GlobeNewswire)
Jul-09-25 07:35AM	Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength? (Zacks)
Jul-08-25 08:09AM	Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report (GlobeNewswire) +13.15%
Jun-30-25 08:55AM	Progyny's Q1 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Jun-26-25 12:33AM	1 Stock Under $50 with Exciting Potential and 2 to Question (StockStory)
Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks)
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
09:10AM	Progyny Adds Pelvic Floor Therapy, Continuing to Close Gaps in Care Across Women's Health (GlobeNewswire)
08:54AM	Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
07:31AM	GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
Jun-10-25 09:02AM	Progyny Joins Amazon's Health Benefits Connector Program as First Women's Health and Family Building Solution (GlobeNewswire)
May-29-25 09:03AM	Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors (GlobeNewswire)
May-20-25 12:01AM	3 Reasons PGNY is Risky and 1 Stock to Buy Instead (StockStory)
May-18-25 11:35PM	Q1 Earnings Outperformers: Progyny (NASDAQ:PGNY) And The Rest Of The Health Insurance Providers Stocks (StockStory)
May-14-25 09:05AM	Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board (GlobeNewswire)
May-12-25 03:58PM	Progyny, Inc. to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-09-25 11:46AM	Q1 2025 Progyny Inc Earnings Call (Thomson Reuters StreetEvents) -9.33%
03:44AM	Progyny Inc (PGNY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions (GuruFocus.com)
May-08-25 06:55PM	Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates (Zacks)
05:55PM	Progyny: Q1 Earnings Snapshot (Associated Press Finance)
04:14PM	Progyny, Inc. Announces First Quarter 2025 Results (GlobeNewswire)
11:40AM	GDRX vs. PGNY: Which Stock Should Value Investors Buy Now? (Zacks)
09:25AM	Progyny Inc (PGNY) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-07-25 05:35PM	Progyny Q1 2025 Earnings Preview (Seeking Alpha)
01:10PM	Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses (Zacks)
May-06-25 01:09PM	Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates? (Zacks)
07:11AM	MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings? (Zacks)
May-05-25 02:48PM	Progyny Stock Sees RS Rating Improve To 73 (Investor's Business Daily)

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm's network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 11 '25	Sale	25.50	459	11,704	46,983	Dec 15 04:12 PM
Livingston Mark S.	Officer	Dec 11 '25	Proposed Sale	25.50	459	11,704		Dec 11 02:55 PM
Swartz Allison	EVP, GC	Dec 04 '25	Sale	24.59	530	13,033	72,719	Dec 08 04:23 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 02 '25	Sale	25.50	213	5,432	47,921	Dec 04 04:17 PM
Swartz Allison	Officer	Dec 04 '25	Proposed Sale	24.59	530	13,033		Dec 04 09:41 AM
Swartz Allison	EVP, GC	Nov 28 '25	Sale	26.87	2,398	64,434	73,657	Dec 02 04:15 PM
Livingston Mark S.	Officer	Dec 02 '25	Proposed Sale	25.50	213	5,432		Dec 02 10:24 AM
Swartz Allison	Officer	Nov 28 '25	Proposed Sale	26.87	2,398	64,434		Nov 28 09:39 AM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Nov 17 '25	Sale	25.50	21,303	543,226	48,358	Nov 19 05:03 PM
Payson Norman	Director	Nov 14 '25	Option Exercise	1.45	36,224	52,525	56,954	Nov 18 04:48 PM
Livingston Mark S.	Officer	Nov 17 '25	Proposed Sale	25.50	21,303	543,226		Nov 17 12:31 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Nov 13 '25	Buy	24.29	79,500	1,930,896	680,251	Nov 17 08:22 AM
Swartz Allison	EVP, GC	Sep 04 '25	Sale	23.53	599	14,094	77,407	Sep 05 04:39 PM
Swartz Allison	Officer	Sep 04 '25	Proposed Sale	23.53	599	14,094		Sep 04 09:35 AM
Swartz Allison	EVP, GC	Aug 28 '25	Sale	22.96	2,398	55,058	79,697	Sep 02 05:04 PM
Swartz Allison	Officer	Aug 28 '25	Proposed Sale	22.96	2,398	55,058		Aug 28 11:28 AM
GORDON KEVIN K	Director	Aug 11 '25	Sale	22.04	2,500	55,088	12,501	Aug 13 06:12 PM
GORDON KEVIN K	Director	Aug 11 '25	Proposed Sale	22.04	2,500	55,088		Aug 11 01:58 PM
Scott Cheryl	Director	Jun 11 '25	Sale	22.07	2,675	59,037	14,112	Jun 12 05:07 PM
Scott Cheryl	Director	Jun 11 '25	Proposed Sale	22.07	2,675	59,039		Jun 11 12:44 PM
Cohen Fred E	Former Director	Jun 03 '25	Proposed Sale	21.68	62,244	1,349,450		Jun 03 12:05 PM

KYTX

Kyverna Therapeutics Inc

URGN

UroGen Pharma Ltd

CDNA

Caredx Inc

NTLA

Intellia Therapeutics Inc

PGNY

Progyny Inc

Upgrade your FINVIZ experience